keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/28424557/vedolizumab-toward-a-personalized-therapy-paradigm-for-people-with-ulcerative-colitis
#1
REVIEW
Robin J Dart, Mark A Samaan, Nick Powell, Peter M Irving
Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory bowel disease, with a characteristic leukocytic infiltration of the mucosa. Immunosuppression including anti-TNF-α therapy is a mainstay of treatment for many; however, systemic immunosuppression is not universally effective and is associated with potential side effects. The gut-tropic integrin α4β7, which is expressed on leukocytes, mediates migration from the circulation to the intestinal mucosa. Vedolizumab is a monoclonal antibody which blocks the egress of leukocytes via α4β7, preventing accumulation in the mucosa, and attenuating inflammation without systemic immunosuppression...
2017: Clinical and Experimental Gastroenterology
https://www.readbyqxmd.com/read/28407755/inflammatory-bowel-disease-ibd-pharmacotherapy-and-the-risk-of-serious-infection-a-systematic-review-and-network-meta-analysis
#2
Chelle L Wheat, Cynthia W Ko, Kindra Clark-Snustad, David Grembowski, Timothy A Thornton, Beth Devine
BACKGROUND: The magnitude of risk of serious infections due to available medical therapies of inflammatory bowel disease (IBD) remains controversial. We conducted a systematic review and network meta-analysis of the existing IBD literature to estimate the risk of serious infection in adult IBD patients associated with available medical therapies. METHODS: Studies were identified by a literature search of PubMed, Cochrane Library, Medline, Web of Science, Scopus, EMBASE, and ProQuest Dissertations and Theses...
April 14, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28370049/editorial-vedolizumab-in-pregnancy-is-gut-selectivity-as-good-for-baby-as-it-is-for-mum
#3
EDITORIAL
H H Shim, C H Seow
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28370036/editorial-vedolizumab-in-pregnancy-is-gut-selectivity-as-good-for-baby-as-it-is-for-mum-authors-reply
#4
EDITORIAL
U Mahadevan, S Vermeire, K Lasch, B Abhyankar, F Bhayat, A Blake, M Dubinsky
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28369329/vedolizumab-induces-long-term-mucosal-healing-in-patients-with-crohn-s-disease-and-ulcerative-colitis
#5
Maja Noman, Marc Ferrante, Raf Bisschops, Gert De Hertogh, Karolien Van den Broeck, Karen Rans, Paul J Rutgeerts, Séverine Vermeire, Gert Van Assche
Introduction.: Vedolizumab has proven efficacy in IBD, but long term mucosal healing in Crohn's disease (CD), as well as the incidence of colorectal neoplasia in IBD, among patients treated with vedolizumab have not been studied. We aimed to document mucosal healing and to explore the risk of colorectal neoplasia with vedolizumab maintenance therapy. Methods.: Surveillance colonoscopy was prospectively scheduled for patients with longstanding UC or CD at a tertiary referral center in the open label extension phase (vedolizumab 300 mg IV q 4 wks) of the Gemini studies (GEMINI LTS, study number NCT00790933)...
March 24, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28362144/long-term-effectiveness-of-vedolizumab-in-inflammatory-bowel-disease-a-national-study-based-on-the-swedish-national-quality-registry-for-inflammatory-bowel-disease-swibreg
#6
Carl Eriksson, Jan Marsal, Daniel Bergemalm, Lina Vigren, Jan Björk, Michael Eberhardson, Pontus Karling, Charlotte Söderman, Pär Myrelid, Yang Cao, Daniel Sjöberg, Mari Thörn, Per Karlén, Erik Hertervig, Hans Strid, Jonas F Ludvigsson, Sven Almer, Jonas Halfvarson
OBJECTIVES: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness. MATERIALS AND METHODS: Patients initiating vedolizumab between 1 June 2014 and 30 May 2015 were identified through the Swedish National Quality Registry for IBD. Prospectively collected data on treatment and disease activity were extracted...
June 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28357697/predictors-of-clinical-response-and-remission-at-1%C3%A2-year-among-a-multicenter-cohort-of-patients-with-inflammatory-bowel-disease-treated-with-vedolizumab
#7
Jessica R Allegretti, Edward L Barnes, Betsey Stevens, Margaret Storm, Ashwin Ananthakrishnan, Vijay Yajnik, Joshua Korzenik
BACKGROUND: Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in phase III trials. AIMS: Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. METHODS: Adult patients completing induction therapy with VDZ were eligible for this study. Clinical response and remission was assessed using the Harvey-Bradshaw Index (HBI) for CD, the Simple Clinical Colitis Activity Index for UC and physician assessment...
March 29, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28337471/intractable-pyoderma-gangrenosum-in-a-crohn-s-disease-patient-on-vedolizumab
#8
Jennifer E Yeh, William G Tsiaras
No abstract text is available yet for this article.
March 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28333288/exposure-efficacy-relationships-for-vedolizumab-induction-therapy-in-patients-with-ulcerative-colitis-or-crohn-s-disease
#9
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn, Brian G Feagan, Walter Reinisch, Bruce E Sands, Miguel Sans, Irving Fox
Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in post hoc analyses of GEMINI study data. Methods: Vedolizumab trough concentrations at Week 6 or 10 were grouped in quartiles and clinical outcome rates calculated. Exposure-efficacy relationships at Week 6 and potential baseline covariate effects were explored using logistic regression and individual predicted cumulative average concentration through Week 6 (Caverage) as exposure measure...
February 17, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28333273/blocking-the-47-integrin-through-vedolizumab-necessary-but-not-sufficient
#10
Erwin Dreesen, Ann Gils
No abstract text is available yet for this article.
March 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28326566/systematic-review-with-meta-analysis-comparative-efficacy-of-biologics-for-induction-and-maintenance-of-mucosal-healing-in-crohn-s-disease-and-ulcerative-colitis-controlled-trials
#11
REVIEW
A Cholapranee, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
BACKGROUND: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. AIM: To perform a systematic review and meta-analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials (RCT) examining mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC...
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28296827/vedolizumab-is-safe-and-effective-in-elderly-patients-with-inflammatory-bowel-disease
#12
Udayakumar Navaneethan, Timothy Edminister, Xiang Zhu, Kiran Kommaraju, Sarah Glover
No abstract text is available yet for this article.
April 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28296823/novel-insights-into-the-mechanisms-of-gut-homing-and-antiadhesion-therapies-in-inflammatory-bowel-diseases
#13
Sebastian Zundler, Markus F Neurath
Therapeutic compounds interfering with T cell trafficking are a new column of inflammatory bowel disease (IBD) treatment. Currently, the anti-α4β7 integrin antibody vedolizumab is successfully used in the clinic and further drugs are likely to follow. Despite these clinical advances, the precise mechanistic background of their action is only gradually elucidated and still a matter of intensive research. Only recently, advances made with the help of new in vivo models and human studies have contributed to shape our concept of T cell trafficking in IBD by deciphering some important and so far unanswered questions...
April 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28296011/vedolizumab-is-safe-and-effective-in-moderate-to-severe-inflammatory-bowel-disease-following-liver-transplantation
#14
Andrew P Wright, Robert J Fontana, Ryan W Stidham
No abstract text is available yet for this article.
March 14, 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28279079/the-safety-of-biological-pharmacotherapy-for-the-treatment-of-ulcerative-colitis
#15
REVIEW
Gionata Fiorino, Stefanos Bonovas, Clelia Cicerone, Mariangela Allocca, Federica Furfaro, Carmen Correale, Silvio Danese
Biological agents are effective in ulcerative colitis (UC). Currently, 3 anti-TNF agents (infliximab, adalimumab, and golimumab) and 1 anti-integrin agent (vedolizumab) are approved for the treatment of UC. The mechanism of action of biologic agents can also give rise to several side effects, some even serious. It remains uncertain to what extent biologic treatments may be associated with an increased rate of infections, malignancies and other adverse events Areas covered: Our aim is to review the relevant data available in the literature and briefly summarize the safety profile of biological therapy in UC...
April 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28276855/the-safety-of-vedolizumab-for-the-treatment-of-ulcerative-colitis
#16
REVIEW
Gregor Novak, Pieter Hindryckx, Reena Khanna, Vipul Jairath, Brian G Feagan
Vedolizumab is a humanized monoclonal antibody to the α4β7-integrin that blocks lymphocyte trafficking to the gut and is approved for treatment of patients with moderate-to-severe ulcerative colitis (UC). The gut-selective mechanism of action has the potential to improve vedolizumab's safety profile compared to other approved biologic drugs. Areas covered: We review the mechanism of action, efficacy and safety of vedolizumab treatment for UC. The positioning of vedolizumab in management algorithms is also discussed...
April 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28271250/cost-effectiveness-of-vedolizumab-compared-with-infliximab-adalimumab-and-golimumab-in-patients-with-ulcerative-colitis-in-the-united-kingdom
#17
Michele R Wilson, Annika Bergman, Helene Chevrou-Severac, Ross Selby, Michael Smyth, Matthew C Kerrigan
OBJECTIVE: To examine the clinical and economic impact of vedolizumab compared with infliximab, adalimumab, and golimumab in the treatment of moderately to severely active ulcerative colitis (UC) in the United Kingdom (UK). METHODS: A decision analytic model in Microsoft Excel was used to compare vedolizumab with other biologic treatments (infliximab, adalimumab, and golimumab) for the treatment of biologic-naïve patients with UC in the UK. Efficacy data were obtained from a network meta-analysis using placebo as the common comparator...
March 8, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28247573/review-article-moving-towards-common-therapeutic-goals-in-crohn-s-disease-and-rheumatoid-arthritis
#18
REVIEW
P B Allen, P Olivera, P Emery, D Moulin, J-Y Jouzeau, P Netter, S Danese, B Feagan, W J Sandborn, L Peyrin-Biroulet
BACKGROUND: Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability. AIM: To review the similarities and differences in treatment goals between CD and rheumatoid arthritis...
March 1, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28243458/combination-therapy-with-vedolizumab-and-etanercept-in-a-patient-with-pouchitis-and-spondylarthritis
#19
Johannes Bethge, Silvia Meffert, Mark Ellrichmann, Claudio Conrad, Susanna Nikolaus, Stefan Schreiber
Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe...
2017: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/28221249/the-%C3%AE-4%C3%AE-1-homing-pathway-is-essential-for-ileal-homing-of-crohn-s-disease-effector-t-cells-in-vivo
#20
Sebastian Zundler, Anika Fischer, Daniela Schillinger, Marie-Theres Binder, Raja Atreya, Timo Rath, Rocío Lopez-Pósadas, Caroline J Voskens, Alastair Watson, Imke Atreya, Clemens Neufert, Markus F Neurath
BACKGROUND: The precise mechanisms controlling homing of T effector (Teff) cells to the inflamed gut in Crohn's disease (CD) are still unclear, and clinical outcome data from patients with inflammatory bowel disease treated with the anti-α4β7 integrin antibody vedolizumab suggest differences between ulcerative colitis and CD. METHODS: Expression of homing molecules was studied with flow cytometry and immunohistochemistry. Their functional role was investigated in in vitro adhesion assays and in a humanized mouse model of T cell homing to the inflamed gut in vivo...
March 2017: Inflammatory Bowel Diseases
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"